Pharmacopeia
DIGOXIN
Core pharmacology
- Class Group
Antiarrhythmic –
Vaughan Williams Class V
Other- Introduction
glycoside derived from the dried leaves of the foxglove
Block Na-K-ATPase pump
- Indications Uses
used in AF and atrial flutter, SVT and in heart failure
- Presentation
PO: tablets 62.5mcg or 250mcg. IV:25-250mcg/ml.
Narrow therapeutic window. Monitoring necessary - 0.5-2mcg/L(~1)- Mechanism of action
i) Na/K ATPase inhibition → ↑ intracell Na → ↓ Na-Ca pump → ↑ intracell Ca → inotropy
ii) direct: ↑ AV node ERP, ↓ V ERP
iii) Indirect: Via Vagus – bradycardia, ↓ A refr. Augmentn of direct ↑ AV node ERP- Onset Peak Duration
onset / duration Oral: 1-2 hours; I.V.: 5-60 mins / 3-4 days
- Adverse Effects Toxicity
Thyroid-Vd
Narrow therapeutic window -monitoring - 0.5-2mcg/L(~1)
Toxic > 2.5- arrhythmias, AV block.
anorexia,N/V/D, lethargy. Altered Red green colour perception. ECG: ↑ PR, ST dep, T fl-attening, ↓QT. (may not indicate toxicity)- Absorption
IV, PO BA 60-80%
- Protein binding
prot bind ~25%; uremia- displaced fm pl prot bind sites
- Volume of distribution
6-7 L/kg
thyroid (↑ in hyper, ↓ hypo).- Metabolism
Stomach:Sequential sugar hydrolysis+ redn of lactone ring by intestinal bacteria
min hepatic, most excr unchanged- Excretion
Urine (50% to 70% unchanged)
- Half-life
36-48 hours
- Route And Dose
IV/PO.
loading 250-500mcg QID then 62.5-125mcg daily- Physiological effects
Positive inotropy. Slows sinus rate and AV-nodal conduction and increases AV-nodal refractoriness through direct electrophysiological and vagotonic effects. Rapid IV administration may cause vasoconstriction. Characteristic ECG effects include PR prolongation, ST depression, T-wave flattening and QT shortening. Mild diuresis.